Stratos Wealth Partners LTD. raised its stake in shares of Allergan PLC. (NYSE:AGN) by 1.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,387 shares of the company’s stock after buying an additional 54 shares during the period. Stratos Wealth Partners LTD.’s holdings in Allergan PLC. were worth $823,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of AGN. State of Alaska Department of Revenue purchased a new position in shares of Allergan PLC. during the first quarter valued at approximately $405,000. Waldron LP purchased a new position in shares of Allergan PLC. during the first quarter valued at approximately $348,000. PGGM Investments purchased a new position in shares of Allergan PLC. during the first quarter valued at approximately $33,213,000. Fisher Asset Management LLC increased its position in shares of Allergan PLC. by 26.0% in the first quarter. Fisher Asset Management LLC now owns 5,099 shares of the company’s stock valued at $1,218,000 after buying an additional 1,051 shares during the period. Finally, Acadian Asset Management LLC increased its position in shares of Allergan PLC. by 437.9% in the first quarter. Acadian Asset Management LLC now owns 1,802 shares of the company’s stock valued at $431,000 after buying an additional 1,467 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Allergan PLC. (AGN) opened at 223.58 on Wednesday. The company has a market cap of $74.74 billion, a P/E ratio of 6.81 and a beta of 1.16. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The firm’s 50 day moving average is $240.49 and its 200-day moving average is $238.48.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the previous year, the firm earned $3.35 earnings per share. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. On average, analysts predict that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be paid a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.25%. Allergan PLC.’s dividend payout ratio is currently 9.95%.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/30/stratos-wealth-partners-ltd-has-823000-position-in-allergan-plc-agn.html.

Several equities analysts have recently commented on the stock. UBS AG reaffirmed a “buy” rating and set a $275.00 price objective on shares of Allergan PLC. in a research note on Monday, May 15th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of Allergan PLC. in a research note on Tuesday, August 22nd. BidaskClub downgraded shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $280.00 price objective (up from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Finally, Argus reaffirmed a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a research note on Monday, August 14th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company. Allergan PLC. has an average rating of “Buy” and an average price target of $275.49.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.